{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:37:00Z","timestamp":1794652620621,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Program for National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81702052"],"award-info":[{"award-number":["81702052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dynamically changed levels of serum cytokines might predict the development of active TB from latent tuberculosis infection (LTBI) and monitor preventive treatment effectiveness. The aim of the study was to identify potential serum cytokines associated with LTBI treatment which might predict active disease development in a Chinese population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Based on a randomized controlled trial aiming to explore short-course regimens for LTBI treatment, the dynamic changes of serum cytokines determined by bead-based multiplex assays were investigated for the participants who developed active TB during follow-up and age and gender matched controls stayed healthy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Totally, 21 patients diagnosed with active tuberculosis (TB) during the 2-year follow-up (12 from treated groups and 9 from untreated controls) and 42 age and gender matched healthy controls (24 from treated groups and 18 from untreated controls) were included in the study. Before treatment, serum IL-1ra was statistically higher among those who developed active disease during follow-up as compared with those stayed healthy. As for treated participants, the levels of IL-1ra were significantly lower after treatment in comparison with those before treatment both in active TB group (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) and non-TB group (<jats:italic>p<\/jats:italic>\u2009=\u20090.009). For untreated participants, the levels of IL-1ra were not statistically different between different time points both in active TB group (<jats:italic>p<\/jats:italic>\u2009=\u20090.078) and non-TB group (<jats:italic>p<\/jats:italic>\u2009=\u20090.265).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results suggested that declined serum level of IL-1ra was associated with LTBI treatment. Further studies are needed to verify whether it could be used to evaluate LTBI treatment and to predict active disease development.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-020-05047-x","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T08:02:49Z","timestamp":1588924969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Serum level of IL-1ra was associated with the treatment of latent tuberculosis infection in a Chinese population"],"prefix":"10.1186","volume":"20","author":[{"given":"Haoran","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouguo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9957-4527","authenticated-orcid":false,"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"5047_CR1","volume-title":"Global tuberculosis report 2018[Z]","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Global tuberculosis report 2018[Z]. Geneva: World Health Organization; 2018."},{"key":"5047_CR2","first-page":"889","volume":"89","author":"H Hartman-Adams","year":"2014","unstructured":"Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection. Am Fam Physician. 2014;89:889\u201396.","journal-title":"Am Fam Physician"},{"key":"5047_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1183\/09031936.00079310","volume":"37","author":"CC Leung","year":"2011","unstructured":"Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with mycobacterium tuberculosis: update 2010. Eur Respir J. 2011;37:690\u2013711.","journal-title":"Eur Respir J"},{"key":"5047_CR4","first-page":"555","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","unstructured":"International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60:555\u201364.","journal-title":"Bull World Health Organ"},{"key":"5047_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.7326\/M14-1019","volume":"161","author":"HR Stagg","year":"2014","unstructured":"Stagg HR, Zenner D, Harris RJ, Mu\u00f1oz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161:419\u201328.","journal-title":"Ann Intern Med"},{"key":"5047_CR6","doi-asserted-by":"publisher","first-page":"1801470","DOI":"10.1183\/13993003.01470-2018","volume":"52","author":"L Gao","year":"2018","unstructured":"Gao L, Zhang H, Xin H, Liu J, Pan S, Li X, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J. 2018;52:1801470.","journal-title":"Eur Respir J"},{"key":"5047_CR7","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1164\/rccm.201502-0232OC","volume":"191","author":"JP Zellweger","year":"2015","unstructured":"Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunschi R, et al. Risk assessment of tuberculosis in contacts by IFN-\u03b3 release assays. A tuberculosis network European trials group study. Am J Respir Crit Care Med. 2015;191:1176\u201384.","journal-title":"Am J Respir Crit Care Med"},{"key":"5047_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","volume":"12","author":"MX Rangaka","year":"2012","unstructured":"Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-\u03b3 release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:45\u201355.","journal-title":"Lancet Infect Dis"},{"key":"5047_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cytogfr.2012.10.002","volume":"24","author":"SR Slight","year":"2013","unstructured":"Slight SR, Khader SA. Chemokines shape the immune responses to tuberculosis. Cytokine Growth Factor Rev. 2013;24:105\u201313.","journal-title":"Cytokine Growth Factor Rev"},{"key":"5047_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000283687","volume":"80","author":"SY Eum","year":"2010","unstructured":"Eum SY, Lee YJ, Min JH, Kwak HK, Hong MS, Kong JH, et al. Association of antigen-stimulated release of tumor necrosis factor-alpha in whole blood with response to chemotherapy in patients with pulmonary multidrug-resistant tuberculosis. Respiration. 2010;80:275\u201384.","journal-title":"Respiration"},{"key":"5047_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/ijmy.ijmy_30_19","volume":"8","author":"HC Mvungi","year":"2019","unstructured":"Mvungi HC, Mbelele PM, Buza JJ, Mpagama SG, Sauli E. Blood cytokine responses to early secreted protein antigen-6\/culture filtrate protein-10 tuberculosis antigens 2 months after antituberculosis treatment among patients with drug-susceptible pulmonary tuberculosis. Int J Mycobacteriol. 2019;8:53\u20139.","journal-title":"Int J Mycobacteriol"},{"key":"5047_CR12","first-page":"132","volume":"75","author":"V Clifford","year":"2017","unstructured":"Clifford V, Tebruegge M, Zufferey C, Germano S, Forbes B, Cosentino L, et al. Mycobacteria-specific cytokine responses as correlates of treatment response in active and latent tuberculosis. J Inf Secur. 2017;75:132\u201345.","journal-title":"J Inf Secur"},{"key":"5047_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/s41598-018-19523-7","volume":"8","author":"AY Leem","year":"2018","unstructured":"Leem AY, Song JH, Lee EH, Lee H, Sim B, Kim SY, et al. Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy. Sci Rep. 2018;8:1159.","journal-title":"Sci Rep"},{"key":"5047_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2334-11-135","volume":"11","author":"BS Kabeer","year":"2011","unstructured":"Kabeer BS, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis. 2011;11:135.","journal-title":"BMC Infect Dis"},{"key":"5047_CR15","first-page":"292","volume":"78","author":"H Xin","year":"2019","unstructured":"Xin H, Zhang H, Cao X, Li X, Li M, Feng B, et al. Serum level of IL-8 is associated with reversion of QuantiFERON-TB gold in-tube tests. J Inf Secur. 2019;78:292\u20138.","journal-title":"J Inf Secur"},{"key":"5047_CR16","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1183\/09031936.00009114","volume":"44","author":"R Sloot","year":"2014","unstructured":"Sloot R, Schim van der Loeff MF, Kouw PM, Borgdorff MW. Yield of tuberculosis contact investigations in Amsterdam: opportunities for improvement. Eur Respir J. 2014;44:714\u201324.","journal-title":"Eur Respir J"},{"key":"5047_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ebiom.2014.12.001","volume":"2","author":"R Sloot","year":"2014","unstructured":"Sloot R, Schim van der Loeff MF, van Zwet EW, Haks MC, Keizer ST, Scholing M, et al. Biomarkers can identify pulmonary tuberculosis in HIV-infected drug users months prior to clinical diagnosis. EBioMedicine. 2014;2:172\u20139.","journal-title":"EBioMedicine"},{"key":"5047_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","volume":"190","author":"R Sloot","year":"2014","unstructured":"Sloot R, van der Loeff MF S, Kouw PM, Borgdorff MW. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med. 2014;190:1044\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"5047_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.micinf.2004.09.004","volume":"7","author":"A Azzurri","year":"2005","unstructured":"Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, et al. IFN-\u03b3-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in mycobacterium tuberculosis infection. Microbes Infect. 2005;7:1\u20138.","journal-title":"Microbes Infect"},{"key":"5047_CR20","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.5588\/ijtld.16.0342","volume":"20","author":"L Petrone","year":"2016","unstructured":"Petrone L, Cannas A, Vanini V, Cuzzi G, Aloi F, Nsubuga M, et al. Blood and urine inducible protein 10 as potential markers of disease activity. Int J Tuberc Lung Dis. 2016;20:1554\u201361.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5047_CR21","doi-asserted-by":"publisher","first-page":"e0152483","DOI":"10.1371\/journal.pone.0152483","volume":"11","author":"M Suzukawa","year":"2016","unstructured":"Suzukawa M, Akashi S, Nagai H, Nagase H, Nakamura H, Matsui H, et al. Combined Analysis of IFN-\u03b3, IL-2, IL-5, IL-10,IL-1ra and MCP-1 in QFT Supernatant Is Useful for Distinguishing Active Tuberculosis from Latent Infection. PLoS One. 2016;11:e0152483.","journal-title":"PLoS One"},{"key":"5047_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.tube.2011.02.006","volume":"91","author":"M Frahm","year":"2011","unstructured":"Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, Cadogan E, et al. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb). 2011;91:250\u20136.","journal-title":"Tuberculosis (Edinb)"},{"key":"5047_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1164\/rccm.201501-0059OC","volume":"192","author":"M Tebruegge","year":"2015","unstructured":"Tebruegge M, Dutta B, Donath S, Ritz N, Forbes B, Camacho-Badilla K, et al. Mycobacteria-specific cytokine responses detect tuberculosis infection and distinguish latent from active tuberculosis. Am J Respir Crit Care Med. 2015;192:485\u201399.","journal-title":"Am J Respir Crit Care Med"},{"key":"5047_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nm.2299","volume":"17","author":"A Harari","year":"2011","unstructured":"Harari A, Rozot V, Bellutti Enders F, Perreau M, Stalder JM, Nicod LP, et al. Dominant TNF-alpha+ mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med. 2011;17:372\u20136.","journal-title":"Nat Med"},{"key":"5047_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tube.2018.08.011","volume":"114","author":"V Clifford","year":"2019","unstructured":"Clifford V, Tebruegge M, Zufferey C, Germano S, Forbes B, Cosentino L, et al. Cytokine biomarkers for the diagnosis of tuberculosis infection and disease in adults in a low prevalence setting. Tuberculosis (Edinb). 2019;114:91\u2013102.","journal-title":"Tuberculosis (Edinb)"},{"key":"5047_CR26","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720\u201332.","journal-title":"Blood"},{"key":"5047_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1359-6101(02)00020-5","volume":"13","author":"WP Arend","year":"2002","unstructured":"Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323\u201340.","journal-title":"Cytokine Growth Factor Rev"},{"key":"5047_CR28","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.156.7.2503","volume":"156","author":"JH Ruth","year":"1996","unstructured":"Ruth JH, Bienkowski M, Warmington KS, Lincoln PM, Kunkel SL, Chensue SW. IL-1 receptor antagonist (IL-1ra) expression, function, and cytokine-mediated regulation during mycobacterial and schistosomal antigen-elicited granuloma formation. J Immunol. 1996;156:2503\u20139.","journal-title":"J Immunol"},{"key":"5047_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4049\/jimmunol.0903856","volume":"185","author":"PL Lin","year":"2010","unstructured":"Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol. 2010;185:15\u201322.","journal-title":"J Immunol"},{"key":"5047_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3904\/kjim.2003.18.3.138","volume":"18","author":"JH Lee","year":"2003","unstructured":"Lee JH, Chang JH. Changes of plasma interleukin-1 receptor antagonist, interleukin-8 and other serologic markers during chemotherapy in patients with active pulmonary tuberculosis. Korean J Intern Med. 2003;18:138\u201345.","journal-title":"Korean J Intern Med"},{"key":"5047_CR31","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1038\/s41564-019-0578-3","volume":"4","author":"DX Ji","year":"2019","unstructured":"Ji DX, Yamashiro LH, Chen KJ, Mukaida N, Kramnik I, Darwin KH, et al. Type I interferon-driven susceptibility to mycobacterium tuberculosis is mediated by IL-1Ra. Nat Microbiol. 2019;4:2128\u201335.","journal-title":"Nat Microbiol"},{"key":"5047_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/RHU.0b013e31812e00a1","volume":"13","author":"LD Settas","year":"2007","unstructured":"Settas LD, Tsimirikas G, Vosvotekas G, Triantafyllidou E, Nicolaides P. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol. 2007;13:219\u201320.","journal-title":"J Clin Rheumatol"},{"key":"5047_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tube.2015.07.002","volume":"95","author":"V Clifford","year":"2015","unstructured":"Clifford V, He Y, Zufferey C, Connell T, Curtis N. Interferon gamma release assays for monitoring the response to treatment for tuberculosis: a systematic review. Tuberculosis (Ed-inb). 2015;95:639\u201350.","journal-title":"Tuberculosis (Ed-inb)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05047-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05047-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05047-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T20:50:55Z","timestamp":1696107055000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05047-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5047"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05047-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol of the present study has been approved by the Ethics Committees of the Institute of Pathogen Biology, Chinese Academy of Medical Sciences (IDs: IPB-2015-5 and IPB-2016-8). All participants have signed the written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. L. G promises that he had no communication with other editors about this article, and would strictly abide by the rules of this journal and not participate in the review PROCESS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"330"}}